机译:Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir
Chongqing Med Univ, Affiliated Hosp 2, Inst Viral Hepatitis, Chongqing, Peoples R China;
Zhejiang Univ, Affiliated Hosp 1, State Key Lab Diag & Treatment Infect Dis, Hangzhou, Zhejiang;
West China Hosp, Dept Infect Dis, Chengdu, Peoples R ChinaPeking Univ, Hosp 1, Ctr Liver Dis, Dept Infect Dis, Beijing, Peoples R ChinaXiamen Univ, Sch Publ Hlth, Natl Inst Diagnost & Vaccine Dev Infect Dis, State Key Lab Mol VaccinolNanjing Med Univ, Affiliated Hosp 1, Dept Infect Dis, Nanjing, Jiangsu, Peoples R ChinaSouthwest China Hosp, Dept Infect Dis, Chongqing, Peoples R ChinaCapital Med Univ, Beijing Youan Hosp, Dept Int Med, Beijing, Peoples R ChinaHuazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept & Inst Infect Dis, Wuhan, Peoples RFudan Univ, Huashan Hosp, Dept Infect Dis, Shanghai, Peoples R China;
entecavir; hepatitis; hepatitis B core antibody; treatment outcome;